Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Oral minoxidil can cause serious heart issues like cardiac hypertrophy and arrhythmias, prompting some users to reduce dosage or switch to topical treatments. Despite significant hair regrowth, side effects such as shortness of breath and chest pains are common concerns.

Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.

The conversation discusses the less impressive results of Pyrilutamide (kx-836) in phase 3 compared to phase 2, with a suggestion that a longer study might show more significant results. One user reports personal success with Pyrilutamide, experiencing no further hair loss and gradual regrowth.

The user has been using finasteride for hair loss and is considering adding RU58841. They ask about RU58841's effectiveness, potential heart side effects, duration of action, dosage increase over time, transitioning to GT20029, and where to find the liquid form.

This post and conversation are about the effects of Minoxidil on renal electrolytes transport in the Loop of Henle. The replies show a lack of interest and a brief summary stating that rectal Minoxidil electrolytes are bad.

The conversation is about a user who experienced negative side effects and poor sleep after using an impure hair loss treatment 'CB' from Wuhan Hengheda Pharm, which did not offer a refund or proper customer service. The user had the product tested, confirming its impurity.

A user experiencing side effects from a 5% minoxidil and 0.1% finasteride topical solution for hair loss reduced their dosage due to numbness and pain in the lower body and is seeking advice on dosage and alternatives like redensyl. They are concerned about the side effects of both medications and are considering adjusting the dose or switching treatments.

Nizoral causes scalp and face itchiness and flakes. Piroctone olamine is suggested as an alternative.

The user is experiencing ongoing hair loss despite using a comprehensive treatment regimen including dutasteride, oral minoxidil, cyproterone acetate, transdermal estradiol, and topical bicalutamide. They suspect cyproterone acetate may be worsening their hair loss and are considering switching to injection monotherapy.

KX-826 hair loss treatment completed trials with mild side effects. GT20029 may be ultimate cure, destroying androgen receptors causing baldness.

The conversation discusses the potential release date of a hair loss treatment called Pyrilutamide. One user suggests it may be available in about 5 years.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Pyrilutamide Phase 2 results are expected in June 2022, with hopes for a better alternative to current treatments.

A person is experimenting with microneedling on one temple while using Minoxidil to address hair loss. They plan to needle weekly and apply Minoxidil twice daily, avoiding application around needling sessions.

The user is using a hair loss treatment regimen that includes RU58841, minoxidil mixed with finasteride, adenosine, dermarolling with lidocaine cream, and biotin. They are questioning if they are dermarolling too aggressively and are willing to accept baldness if no improvement is seen in 6 months.

The conversation is about a user experiencing hair thinning potentially due to excessive microneedling while using finasteride and minoxidil. Many suggest reducing microneedling frequency and considering alternative treatments like dutasteride or a hair transplant.

The results of using Pyrilutamide, a hair loss treatment available on the gray market, and other treatments such as Minoxidil, Finasteride and RU58841.

The user experienced increased hair loss and scalp itchiness despite using finasteride and plans to resume minoxidil and start microneedling. They are considering using clay, Aveda thickening tonic, and a beanie to manage the appearance of thinning hair.

The conversation discusses hair loss treatments, mentioning minoxidil, finasteride, RU58841, VDPHL, GT20029, and follicle cloning as potential solutions. It also reveals that the discussion about PP405 was an April Fool's joke.

The user was prescribed 5mg Finasteride and later switched to 1mg for hair loss, also using topical Minoxidil. They are concerned about potential lasting side effects from the initial 5mg dosage.

The conversation is about using pyrilutamide for hair loss, with the original poster also using minoxidil and nizoral for maintenance. The poster experienced side effects from finasteride and is seeking feedback from long-term pyrilutamide users.

An 18-year-old is seeking advice on microneedling while using RU58841 for hair loss. Recommendations include using a derma pen with 0.5mm needles every two weeks and avoiding RU application for 24 hours post-microneedling to prevent absorption into the bloodstream.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. User considers trying Fluridil, questioning if it has no side effects.

Switching from propylene glycol to glycerin in topical finasteride may reduce systemic absorption and side effects while maintaining local scalp DHT suppression. Concerns exist about glycerin's ability to deliver the full dose to hair follicles.

FOL-005 claims to be more effective than Minoxidil and Finasteride but lacks anti-DHT properties, leading to potential reduced efficacy over time. Concerns are raised about misleading marketing and the safety of alternative treatments like Pyrilutamide and Clascoterone.

Increased scalp itching during shedding phases while on finasteride treatment may coincide with hair regrowth and recovery. This suggests that itching might not always indicate continued hair loss and could encourage persistence with the treatment.

A user experienced hair retention but sexual side effects after using dutasteride for a year. Others shared similar experiences with finasteride and dutasteride, suggesting consulting a doctor for persistent issues.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.